Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, reports that Rik J Deitsch, Chief Executive Officer, was interviewed by The Wall Street Transcript ("TWST"). The interview has been included in TWST's February 2006 Biotechnology Report and is available to TWST's subscribers on their website www.twst.com.
In the interview, Mr. Deitsch discusses Nutra Pharma's focus as an incubator of undervalued biotechnology holdings. He also focuses on the research being conducted in diseases that lack therapeutic options, specifically HIV/AIDS and Multiple Sclerosis (MS). Additionally, he discusses the Company's breakthrough medical diagnostic test kits being distributed globally through its wholly owned subsidiary Designer Diagnostics.
The Wall Street Transcript is a leading information source for professional investors seeking successful new investment ideas. The Wall Street Transcript conducts in-depth interviews of CEOs with leading public companies, analysts and money managers to give sophisticated investors an unscripted, first-hand perspective that enables them to make informed investment decisions.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Wall Street Transcript interview with Nutra Pharma CEO Rik J. Deitsch should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.